

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SinoMab BioScience Limited

中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

CHANGES IN SHAREHOLDING OF CONTROLLING SHAREHOLDERS

The board of directors (the “**Board**”) of SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”) has been informed that, on 26 May 2020, Forbest Capital Investment Group Limited (“**Forbest Capital**”) as seller, which is one of the controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) of the Company, has entered into a sale and purchase agreement (the “**Sale and Purchase Agreement**”) with, among others, Grogene Technology Limited (“**Grogene**”) as purchaser, pursuant to which Forbest Capital agreed to sell and Grogene agreed to purchase 41,331,640 shares of the Company (the “**Sale Shares**”) at a price of HK\$3.50 per Sale Share. The Sale Shares represent approximately 4.11% of the total issued share capital of the Company as at the date of this announcement. Grogene is wholly-owned by Mr. Jing QIANG (“**Mr. Qiang**”), an executive director and president of the Company and the spouse of Ms. Wenyi LIU (“**Ms. Liu**”), a non-executive director of the Company.

Reference is made to the Company’s prospectus dated 31 October 2019 (the “**Prospectus**”). Forbest Capital, Skytech Technology Limited and others (each a “**Concert Party**”) entered into the Concert Party Agreement (as defined in the Prospectus) on 30 October 2017, as a result of which each Concert Party is deemed to be a controlling shareholder of the Company.

Immediately before entering into the Sale and Purchase Agreement, Forbest Capital was deemed to be interested in 389,469,200 shares of the Company (representing approximately 38.71% of the total issued share capital of the Company) and Mr. Qiang was deemed to be interested in 212,889,400 shares of the Company (representing approximately 21.16% of the total issued share capital of the Company).

Upon completion of the Sale and Purchase Agreement, Forbest Capital will be deemed to be interested in 348,137,560 shares of the Company (representing approximately 34.60% of the total issued share capital of the Company), each of Mr. Qiang and Ms. Liu will be deemed to be interested in 254,221,040 shares of the Company (representing approximately 25.27% of the total issued share capital of the Company), and Forbest Capital and each of the other Concert Parties will remain as a controlling shareholder of the Company.

By Order of the Board
SinoMab BioScience Limited
Dr. Shui On LEUNG

Executive Director, Chairman and Chief Executive Director

Hong Kong, 26 May 2020

As at the date of this announcement, the executive directors of the Company are Dr. Shui On LEUNG and Mr. Jing QIANG, the non-executive directors of the Company are Ms. Wenyi LIU, Dr. Haigang CHEN, Mr. Senlin LIU, Mr. Huiyuan MA and Mr. Xun DONG, and the independent non-executive directors of the Company are Mr. Dylan Carlo TINKER, Mr. Michael James Connolly HOGAN, Mr. Ping Cho Terence HON and Mr. George William Hunter CAUTHERLEY.